Adenocarcinoma of the Sinonasal Tract: A Review of the National Cancer Database
09 March 2019
28 July 2019
12 September 2019 (online)
Background Sinonasal adenocarcinoma (SNAC) is a rare malignancy arising from mucus-secreting glandular tissue. Limited large-scale studies are available due to its rarity. We evaluated SNAC in the National Cancer Database (NCDB), a source that affords multi-institutional, population studies of rare cancers and their outcomes.
Methods The NCDB was queried for adenocarcinoma in the sinonasal tract. Multivariate analyses were performed to evaluate for factors contributing to overall survival (OS).
Results A total of 553 patients were identified. The cohort was composed of 59.3% males. The nasal cavity was the most common primary site, representing 44.1% of cases. About 5.7% of patients presented with nodal disease, while 3.3% had distant metastases. About 40.6% of cases presented with stage IV disease. About 73.5% of patients underwent surgery, 54.2% received radiation therapy, and 27.7% had chemotherapy. Median OS was 71.7 months, while OS at 1, 2, and 5 years was 82, 73.0, and 52%, respectively. On multivariate analysis, advanced age (hazard ratio [HR]: 1.04; 95% confidence interval [CI]: 1.02–1.05), Charlson–Deyo score of 1 (HR: 1.99; 95% CI: 1.20–3.30), advanced tumor grade (HR: 2.73; 95% CI: 1.39–5.34), and advanced tumor stage (HR: 2.71; 95% CI: 1.33–5.50) were associated with worse OS, whereas surgery (HR: 0.34; 95% CI: 0.20–0.60) and radiation therapy (HR: 0.55; 95% CI: 0.33–0.91), but not chemotherapy (HR: 1.16; 95% CI: 0.66–2.05), predicted improved OS.
Conclusions SNAC is a rare malignancy with 5-year survival approximating 50%. Surgery and radiation therapy, but not chemotherapy, are associated with improved survival, and likely play a critical role in the interdisciplinary management of SNAC.
KeywordsNational Cancer Database - sinonasal adenocarcinoma - skull base - cranial base - nose and paranasal sinuses - outcomes/cost-effectiveness
* Neil Patel and Ivy Maina contributed equally to this work.
- 1 Leivo I. Sinonasal adenocarcinoma: update on classification, immunophenotype and molecular features. Head Neck Pathol 2016; 10 (01) 68-74
- 2 Kılıç S, Samarrai R, Kılıç SS, Mikhael M, Baredes S, Eloy JA. Incidence and survival of sinonasal adenocarcinoma by site and histologic subtype. Acta Otolaryngol 2017; 1-7 . Doi: 10.1080/00016489.2017.1401229
- 3 Bhayani MK, Yilmaz T, Sweeney A. , et al. Sinonasal adenocarcinoma: a 16-year experience at a single institution. Head Neck 2014; 36: 1490-1496
- 4 Lund VJ, Chisholm EJ, Takes RP. , et al. Evidence for treatment strategies in sinonasal adenocarcinoma. Head Neck 2012; 34 (08) 1168-1178
- 5 Orvidas LJ, Lewis JE, Weaver AL, Bagniewski SM, Olsen KD. Adenocarcinoma of the nose and paranasal sinuses: a retrospective study of diagnosis, histologic characteristics, and outcomes in 24 patients. Head Neck 2005; 27 (05) 370-375
- 6 Bhayani MK, Yilmaz T, Sweeney A. , et al. Sinonasal adenocarcinoma: a 16-year experience at a single institution. Head Neck 2014; 36 (10) 1490-1496
- 7 Choussy O, Ferron C, Védrine PO. , et al. Adenocarcinoma of ethmoid: A GETTEC retrospective multicenter study of 418 cases. Laryngoscope 2008; 118 (03) 437-443
- 8 De Gabory L, Maunoury A, Maurice-Tison S. , et al. Long-term single-center results of management of ethmoid adenocarcinoma: 95 patients over 28 years. Ann Surg Oncol 2010; 17 (04) 1127-1134
- 9 Binazzi A, Ferrante P, Marinaccio A. Occupational exposure and sinonasal cancer: a systematic review and meta-analysis. BMC Cancer 2015; 15 (01) DOI: 10.1186/s12885-015-1042-2.
- 10 Nissen MS, Stokholm ZA, Christensen MS. , et al. Sinonasal adenocarcinoma following styrene exposure in the reinforced plastics industry. 2018: 1-3 . Doi: 10.1136/oemed-2017-104974.
- 11 Turri-Zanoni M, Battaglia P, Lambertoni A. , et al. Treatment strategies for primary early-stage sinonasal adenocarcinoma: a retrospective bi-institutional case-control study. J Surg Oncol 2015; 112 (05) 561-567
- 12 Van Gerven L, Jorissen M, Nuyts S, Hermans R, Vander Poorten V. Long-term follow-up of 44 patients with adenocarcinoma of the nasal cavity and sinuses primarily treated with endoscopic resection followed by radiotherapy. Head Neck 2011; 33 (06) 898-904
- 13 Meccariello G, Deganello A, Choussy O. , et al. Endoscopic nasal versus open approach for the management of sinonasal adenocarcinoma: A pooled-analysis of 1826 patients. Eisele DW. , ed. Head Neck. 2016 ;38(S1): E2267-E2274 . Doi:10.1002/hed.24182.
- 14 D'Aguillo CM, Kanumuri VV, Khan MN. , et al. Demographics and survival trends of sinonasal adenocarcinoma from 1973 to 2009. Int Forum Allergy Rhinol 2014; 4 (09) 771-776 . Doi: 10.1002/alr.21342
- 15 American College of Surgeons. National Cancer Database. https://www.facs.org/quality-programs/cancer/ncdb . Published 2018. Accessed March 13, 2018.
- 16 Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med 2008; 3 DOI: 10.1186/1751-0473-3-17.
- 17 Klintenberg C, Olofsson J, Hellquist H, Sökjer H. Adenocarcinoma of the ethmoid sinuses. A review of 28 cases with special reference to wood dust exposure. Cancer 1984; 54 (03) 482-488 . Doi: 10.1002/1097-0142(19840801)54:3<482:AID-CNCR2820540317>3.0.CO;2-V
- 18 Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and Genetics of Head and Neck Tumours. WHO Classif Tumours 2005; 9: 163-175 . Doi:10.1016/j.urology.2004.09.048.
- 19 Allen MW, Schwartz DL, Rana V. , et al. Long-term radiotherapy outcomes for nasal cavity and septal cancers. Int J Radiat Oncol Biol Phys 2008; 71 (02) 401-406
- 20 Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012; 34 (06) 877-885
- 21 Gatta G, Bimbi G, Ciccolallo L, Zigon G, Cantu' G. , The Eurocare Working Group. Survival for ethmoid sinus adenocarcinoma in European populations. Acta Oncol (Madr) 2009; 48 (07) 992-998
- 22 Michel J, Radulesco T, Penicaud M, Mancini J, Dessi P. Sinonasal adenocarcinoma: clinical outcomes and predictive factors. Int J Oral Maxillofac Surg 2017; 46 (04) 422-427
- 23 Roux FX, Brasnu D, Devaux B. , et al. Ethmoid sinus carcinomas: results and prognosis after neoadjuvant chemotherapy and combined surgery-A 10-Year experience. Surg Neurol 1994; 42 (02) 98-104
- 24 Brasnu D, Laccourreye O, Bassot V, Laccourreye L, Naudo P, Roux FX. Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base. Arch Otolaryngol Head Neck Surg 1996; 122 (07) 765-768 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8663951
- 25 Nagano H, Yoshifuku K, Deguchi K, Kurono Y. Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): a case report. Auris Nasus Larynx 2010; 37 (02) 238-243
- 26 Lee YY, Dimery IW, Van Tassel P, De Pena C, Blacklock JB, Goepfert H. Superselective intra-arterial chemotherapy of advanced paranasal sinus tumors. Arch Otolaryngol Neck Surg 1989; 115 (04) 503-511
- 27 Hoeben A, van de Winkel L, Hoebers F. , et al. Intestinal-type sinonasal adenocarcinomas: The road to molecular diagnosis and personalized treatment. Eisele DW. , ed. Head Neck. 2016 ;38(10): 1564-1570 . Doi:10.1002/hed.24416.
- 28 Lombardi G, Zustovich F, Della Puppa A. , et al. Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma. J Neurooncol 2011; 104 (01) 381-386
- 29 Licitra L, Suardi S, Bossi P. , et al. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol 2004; 22 (24) 4901-4906
- 30 Knegt PP, Ah-See KW, vd Velden LA, Kerrebijn J. Adenocarcinoma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil may be the optimal treatment. Arch Otolaryngol Head Neck Surg 2001; 127 (02) 141-146 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed5&NEWS=N&AN=2001072880
- 31 Riobello C, Vivanco B, Reda S. , et al. Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer. Head Neck 2017; 2018 DOI: 10.1002/hed.25067.
- 32 Brookhart MA, Sturmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care 2010; 48 (6, Suppl): S114-S120